Want to see SG:T14 full AI Analyst Report?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (T14) AI Stock Analysis
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
(SGX:T14)
The score is supported primarily by strong financial resilience (very low leverage and solid cash flow), but is held back by weakening revenue/earnings trends and clearly bearish technical indicators (price below major moving averages with negative MACD). A high dividend yield helps, but the higher P/E limits the valuation boost.
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (T14) vs. iShares MSCI Singapore ETF (EWS)
- Market Cap
- $3.96B
- Dividend Yield
- 26.76%
- Average Volume (3M)
- 141.74K
- Price to Earnings (P/E)
- 36.6
- Beta (1Y)
- 0.22
- Revenue Growth
- -18.50%
- EPS Growth
- -74.83%
- Country
- Singapore
- Employees
- 3,890
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Business Overview & Revenue Model
Company Description
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (TPDRTG), a prominent pharmaceutical group operating with its various subsidiaries, primarily serves the People's Republic of China. Its core focus lies in the production and sale of tradit...
How the Company Makes Money
null
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Financial Statement Overview
Summary
Strong financial stability driven by an excellent balance sheet (very low leverage; balance sheet score 90) and solid cash generation (cash flow score 68). Offsetting this, the income statement shows weakening momentum with contracting revenue (~-5.2%) and a sharp step-down in net income versus 2024–2025 despite still-healthy margins (income statement score 62).
Income Statement
62PositiveBalance Sheet
90Very PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.71B | 4.92B | 7.31B | 8.22B | 8.25B | 6.91B |
| Gross Profit | 3.51B | 3.64B | 3.52B | 3.62B | 3.29B | 2.76B |
| EBITDA | 996.69M | 2.61B | 2.74B | 1.26B | 1.11B | 991.28M |
| Net Income | 847.52M | 2.13B | 2.23B | 986.71M | 861.79M | 769.14M |
Balance Sheet | ||||||
| Total Assets | 10.54B | 11.69B | 10.77B | 10.23B | 10.16B | 9.07B |
| Cash, Cash Equivalents and Short-Term Investments | 3.53B | 1.02B | 3.94B | 2.15B | 2.88B | 2.28B |
| Total Debt | 98.38M | 62.56M | 27.26M | 325.58M | 257.91M | 33.17M |
| Total Liabilities | 4.52B | 4.59B | 2.92B | 3.58B | 3.61B | 2.55B |
| Stockholders Equity | 5.94B | 7.10B | 7.84B | 6.60B | 6.52B | 6.36B |
Cash Flow | ||||||
| Free Cash Flow | 777.35M | 342.45M | 806.86M | 547.56M | 569.34M | 695.45M |
| Operating Cash Flow | 890.12M | 461.07M | 924.67M | 688.49M | 677.25M | 852.40M |
| Investing Cash Flow | 831.74M | -1.41B | 342.31M | -744.21M | -12.28M | -311.85M |
| Financing Cash Flow | -2.89B | -980.88M | -319.89M | -836.65M | -236.62M | -244.70M |
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Peers Comparison
Overall Rating
- SG:T1465Neutral
SG:42C53Neutral
SG:8YY40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SG:T14 | 65Neutral | $3.96B | 36.55 | 11.47% | 26.76% | -18.50% | -74.83% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| SG:42C | 53Neutral | SGD 558.96M | -61.45 | -81.85% | ― | 3.27% | 43.59% |
| SG:8YY | 40Underperform | SGD 41.60M | -12.63 | -181.49% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SG:T14 | Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S | 2.61 | 0.29 | 12.69% | |
| SG:1J5 | Hyphens Pharma International Ltd. | 0.36 | 0.02 | 4.65% | |
| SG:42C | iX Biopharma Ltd. | 0.51 | 0.40 | 355.36% | |
| SG:546 | Medtecs International Corporation Ltd. | 0.10 | -0.02 | -18.40% | |
| SG:8YY | Biolidics Ltd. | 0.02 | 0.00 | 4.35% | |
| SG:BFK | Pharmesis International Ltd. | 0.10 | -0.28 | -73.96% |
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Corporate Events
Tianjin Da Ren Tang Board Clears FY2026 Half-Year Reports and Governance Changes
The board of Tianjin Pharmaceutical Da Ren Tang Group convened its seventh meeting for FY2026 on 13 August 2026, confirming compliance with PRC Company Law, Securities Law and the firm’s Articles of Association. Directors approved the company&#...
Tianjin Da Ren Tang Redirects Placement Proceeds to Working Capital After Project Cessations
Tianjin Pharmaceutical Da Ren Tang Group reported on the status of net proceeds from its 2015 A-share placement, confirming strict compliance with Chinese regulatory requirements for the deposit and use of funds. As at 30 June 2026, the company had d...
Tianjin Pharmaceutical Da Ren Tang Updates Risk Review of Group Finance Unit
Tianjin Pharmaceutical Da Ren Tang Group has released its latest semi-annual continuous risk assessment report on Tianjin Pharmaceutical Group Finance Co., Ltd., a related finance company within the Tianjin Pharmaceutical Holdings group. The disclosu...
Tianjin Da Ren Tang Proposes Governance-Focused Amendments to Articles of Association
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has proposed amendments to its Articles of Association to align its corporate governance with the revised PRC Company Law and the China Securities Regulatory Commission’s 2025 guideli...
Tianjin Da Ren Tang Wins Approval for New Sustained-Release Diabetes Drug
Xinxin Pharmaceutical Plant, a branch of Tianjin Pharmaceutical Da Ren Tang Group, has obtained a Drug Registration Certificate from China’s National Medical Products Administration for Saxagliptin and Metformin Hydrochloride Sustained-release...
Tianjin Pharmaceutical Da Ren Tang Board Clears Key Related-Party Distribution and Logistics Deals
The board of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited convened its sixth meeting for the 2026 financial year on 7 August 2026, combining a physical session with teleconference in compliance with Chinese corporate and securities re...
Tianjin Da Ren Tang Sets RMB113m Distribution Deal With Related Pharma Affiliates
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited plans to enter an annual distribution agreement via its Health Technology Industry Development Branch with Tianjin Pharmaceutical Group Taiping Medicine and Tianjin Zhongxin Medicine, both...
Tianjin Da Ren Tang Sets RMB19m Logistics Deal With Affiliate Taiping Medicine
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited plans to replace its expiring third-party warehousing contract by engaging Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. for warehousing and logistics services through its Health...
Controlling Shareholder of Tianjin Pharmaceutical Da Ren Tang Slightly Raises Stake in S-Shares
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, previously known as Tianjin Zhong Xin Pharmaceutical Group, is a China-based pharmaceutical firm with both A-shares and S-shares, the latter traded on the Singapore Exchange. Its controlli...
Tianjin Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, formerly Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, is a China-based pharmaceutical group operating through multiple subsidiaries. The company is subject to listing rules...
Tianjin Da Ren Tang Sees Headline Profit Slump, Core Earnings Edge Higher in 1H 2026
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has issued an earnings estimate for the six months ended June 30, 2026, projecting net profit attributable to equity holders at RMB620 million to RMB660 million. This headline figure repres...
Tianjin Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy
The board of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has issued its latest monthly update on the bankruptcy liquidation of Tianjin Shin Poong Pharmaceutical Co., Ltd., a 55%-owned subsidiary in China. The company reports that the...
Tianjin Da Ren Tang Refines Board Committees and Overhauls 2026 Pay Framework
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has reshuffled its board committees following the retirement of independent director Liew Yoke Pheng Joseph and the appointment of new independent director Zhai Shuping. Zhai now chairs the...
Tianjin Da Ren Tang Shareholders Back All FY2025 AGM Resolutions
Shareholders of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited approved all resolutions at the annual general meeting for the year ended 31 December 2025, held in Tianjin with concurrent video participation in Singapore. The meeting cov...
Tianjin Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy Proceedings
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has provided its latest monthly update on the bankruptcy liquidation of Tianjin Shin Poong Pharmaceutical Co., Ltd., a 55%-owned subsidiary in China. The board reiterated its responsibility...
Tianjin Da Ren Tang Schedules Online Briefing on FY2025 and Q1 2026 Results
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited will host an online investor conference on 10 June 2026 to discuss its full-year 2025 financial results and unaudited results for the three months ended 31 March 2026. The session, held via...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 20, 2026